Optimal dilution to be determined by the researcher.
Specificity and Use
TRAF3IP2 / ACT1 antibody was raised against synthetic peptide corresponding to amino acids 2 - 15 of human CIKS. ( N-TERMINAL ).
N-Terminus
Recognizes an epitope within the N-terminal region of CIKS (for connection to IKK and SAPK/JNK), also known as Act 1. CIKS has been shown to interact directly with the regulatory subunit of I Kappa Kinase (IKK), resulting in the activation of NF kB. CIKS Act 1 is ubiquitously expressed in human tissue. Detects a band of approximately 63kD by Western blotting
TRAF3IP2 Antibody, C6orf2 Antibody, C6orf4 Antibody, C6orf5 Antibody, CIKS Antibody, DKFZP586G0522 Antibody, Connection to IKK and SAPK/JNK Antibody, ACT1 Antibody, Adapter protein CIKS Antibody, NFkB-activating protein ACT1 Antibody, PSORS13 Antibody, TRAF3-interacting protein 2 Antibody, C6orf6 Antibody, TRAF3 interacting protein 2 Antibody
Nuclear factor kappa B (NF-kB) is a ubiquitous transcription factor and an essential mediator of gene expression during activation of immune and inflammatory responses. NF-kB mediates the expression of a great variety of genes in response to extracellular stimuli. NF-kB associates with IkB proteins in the cell cytoplasm, which inhibit NF-kB activity. IkB is phosphorylated by IkB kinase (IKK) complex that contains IKKa, IKKb, and IKKg.